Tempus AI, Inc. (TEM) EV/Assets Ratio: 4.29x
Is Tempus AI, Inc.’s EV/Assets ratio high or low?
Tempus AI, Inc.'s EV/Assets ratio of 4.29x is 45% below its 2-year average of 7.86x, near the low end of its 2-year range (3.34x–17.50x).
As of Friday, June 12, 2026. 31.20% below its 12-month average of 6.24x.
TEM EV/Assets Ratio Chart
TEM Average EV/Assets Ratio Chart
TEM Current vs Average EV/Assets Ratio Chart
TEM EV/Assets Ratio Metrics
EV/ASSETS RATIO
4.29x
EV/ASSETS RATIO AVG TTM
6.24x
EV/ASSETS RATIO AVG 3Y
7.86x
EV/ASSETS RATIO AVG 5Y
7.86x
EV/ASSETS RATIO AVG 10Y
7.86x
EV/ASSETS RATIO AVG 15Y
7.86x
EV/ASSETS RATIO AVG 20Y
7.86x
CURRENT VS TTM AVG
-31.20%
CURRENT VS 3Y AVG
-45.41%
CURRENT VS 5Y AVG
-45.41%
CURRENT VS 10Y AVG
-45.41%
CURRENT VS 15Y AVG
-45.41%
CURRENT VS 20Y AVG
-45.41%
TEM Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 4.29x | 6.24x | 7.86x | 7.86x |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 1.56x | 1.50x | 1.60x | 1.95x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 0.89x | 0.88x | 0.89x | 0.99x |
| Baxter International Inc. (BAX) | $10.58B | 0.92x | 0.91x | 1.05x | 1.32x |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 3.31x | 5.94x | 7.31x | 5.78x |
| Align Technology, Inc. (ALGN) | $12.64B | 1.85x | 1.75x | 2.56x | 3.76x |
| Solventum Corporation (SOLV) | $13.72B | 1.31x | 1.27x | 1.28x | 1.28x |
| Hologic, Inc. (HOLX) | $16.97B | 1.91x | 1.84x | 1.98x | 2.08x |
| 23andMe Holding Co. (ME) | $15.31M | 0.03x | 0.41x | 0.28x | 0.81x |
| Moderna, Inc. (MRNA) | $19.70B | 1.65x | 1.14x | 1.48x | 2.53x |
Tempus AI, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The EV/Assets ratio for TEM stock is 4.29x.
- Is Tempus AI, Inc.'s EV/Assets ratio high or low?
- Tempus AI, Inc.'s EV/Assets ratio of 4.29x is 45% below its 2-year average of 7.86x, near the low end of its 2-year range (3.34x–17.50x).
- What is the TTM average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The TTM average EV/Assets ratio for TEM stock is 6.24x.
- What is the 3Y average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The 3Y average EV/Assets ratio for TEM stock is 7.86x.
- What is the 5Y average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The 5Y average EV/Assets ratio for TEM stock is 7.86x.
- What is the 10Y average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The 10Y average EV/Assets ratio for TEM stock is 7.86x.
- What is the 15Y average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The 15Y average EV/Assets ratio for TEM stock is 7.86x.
- What is the 20Y average EV/Assets ratio for Tempus AI, Inc. (TEM)?
- The 20Y average EV/Assets ratio for TEM stock is 7.86x.
Tempus AI, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-11 | 4.29x |
| 2026-06-10 | 4.28x |
| 2026-06-09 | 4.23x |
| 2026-06-08 | 4.21x |
| 2026-06-05 | 4.03x |
| 2026-06-04 | 4.52x |
| 2026-06-03 | 4.12x |
| 2026-06-02 | 4.30x |
| 2026-06-01 | 4.56x |
| 2026-05-29 | 4.37x |
| 2026-05-28 | 4.44x |
| 2026-05-27 | 4.09x |
| 2026-05-26 | 4.05x |
| 2026-05-22 | 4.01x |
| 2026-05-21 | 4.03x |
| 2026-05-20 | 3.98x |
| 2026-05-19 | 3.95x |
| 2026-05-18 | 3.79x |
| 2026-05-15 | 3.82x |
| 2026-05-14 | 3.95x |
| 2026-05-13 | 3.98x |
| 2026-05-12 | 4.07x |
| 2026-05-11 | 4.20x |
| 2026-05-08 | 4.32x |
| 2026-05-07 | 4.28x |
| 2026-05-06 | 4.62x |
| 2026-05-05 | 4.67x |
| 2026-05-04 | 4.37x |
| 2026-05-01 | 4.31x |
| 2026-04-30 | 4.34x |
| 2026-04-29 | 3.92x |
| 2026-04-28 | 4.01x |
| 2026-04-27 | 4.13x |
| 2026-04-24 | 4.09x |
| 2026-04-23 | 4.03x |
| 2026-04-22 | 4.35x |
| 2026-04-21 | 4.32x |
| 2026-04-20 | 4.44x |
| 2026-04-17 | 4.37x |
| 2026-04-16 | 4.26x |
| 2026-04-15 | 4.41x |
| 2026-04-14 | 3.89x |
| 2026-04-13 | 3.62x |
| 2026-04-10 | 3.38x |
| 2026-04-09 | 3.48x |
| 2026-04-08 | 3.73x |
| 2026-04-07 | 3.68x |
| 2026-04-06 | 3.72x |
| 2026-04-02 | 3.72x |
| 2026-04-01 | 3.70x |
| 2026-03-31 | 3.56x |
| 2026-03-30 | 3.34x |
| 2026-03-27 | 3.36x |
| 2026-03-26 | 3.58x |
| 2026-03-25 | 3.67x |
| 2026-03-24 | 3.83x |
| 2026-03-23 | 3.86x |
| 2026-03-20 | 3.69x |
| 2026-03-19 | 3.83x |
| 2026-03-18 | 3.82x |
| 2026-03-17 | 3.99x |
| 2026-03-16 | 3.99x |
| 2026-03-13 | 3.92x |
| 2026-03-12 | 3.89x |
| 2026-03-11 | 4.13x |
| 2026-03-10 | 3.99x |
| 2026-03-09 | 4.10x |
| 2026-03-06 | 4.10x |
| 2026-03-05 | 4.16x |
| 2026-03-04 | 4.02x |
| 2026-03-03 | 4.03x |
| 2026-03-02 | 4.18x |
| 2026-02-27 | 4.17x |
| 2026-02-26 | 4.34x |
| 2026-02-25 | 4.21x |
| 2026-02-24 | 4.53x |
| 2026-02-23 | 4.69x |
| 2026-02-20 | 4.77x |
| 2026-02-19 | 4.90x |
| 2026-02-18 | 4.60x |
| 2026-02-17 | 4.33x |
| 2026-02-13 | 4.28x |
| 2026-02-12 | 4.19x |
| 2026-02-11 | 4.41x |
| 2026-02-10 | 4.58x |
| 2026-02-09 | 4.68x |
| 2026-02-06 | 4.51x |
| 2026-02-05 | 4.32x |
| 2026-02-04 | 4.40x |
| 2026-02-03 | 4.59x |
| 2026-02-02 | 4.79x |
| 2026-01-30 | 4.89x |
| 2026-01-29 | 5.17x |
| 2026-01-28 | 5.25x |
| 2026-01-27 | 5.42x |
| 2026-01-26 | 5.48x |
| 2026-01-23 | 5.31x |
| 2026-01-22 | 5.54x |
| 2026-01-21 | 5.31x |
| 2026-01-20 | 5.42x |
| 2026-01-16 | 5.69x |
| 2026-01-15 | 5.58x |
| 2026-01-14 | 5.61x |
| 2026-01-13 | 5.45x |
| 2026-01-12 | 5.61x |
| 2026-01-09 | 5.38x |
| 2026-01-08 | 5.54x |
| 2026-01-07 | 5.65x |
| 2026-01-06 | 5.63x |
| 2026-01-05 | 5.26x |
| 2026-01-02 | 5.08x |
| 2025-12-31 | 4.83x |
| 2025-12-30 | 4.93x |
| 2025-12-29 | 5.01x |
| 2025-12-26 | 5.11x |
| 2025-12-24 | 5.23x |
| 2025-12-23 | 5.26x |
| 2025-12-22 | 5.35x |
| 2025-12-19 | 5.24x |
| 2025-12-18 | 5.07x |
| 2025-12-17 | 5.25x |
| 2025-12-16 | 5.52x |
| 2025-12-15 | 5.56x |
| 2025-12-12 | 5.71x |
| 2025-12-11 | 5.96x |
| 2025-12-10 | 6.05x |
| 2025-12-09 | 6.12x |
| 2025-12-08 | 6.21x |
| 2025-12-05 | 6.18x |
| 2025-12-04 | 6.15x |
| 2025-12-03 | 6.04x |
| 2025-12-02 | 5.97x |
| 2025-12-01 | 5.98x |
| 2025-11-28 | 6.27x |
| 2025-11-26 | 6.22x |
| 2025-11-25 | 6.19x |
| 2025-11-24 | 6.13x |
| 2025-11-21 | 5.69x |
| 2025-11-20 | 5.34x |
| 2025-11-19 | 5.60x |
| 2025-11-18 | 5.42x |
| 2025-11-17 | 5.39x |
| 2025-11-14 | 5.55x |
| 2025-11-13 | 5.51x |
| 2025-11-12 | 5.75x |
| 2025-11-11 | 5.79x |
| 2025-11-10 | 5.80x |
| 2025-11-07 | 5.79x |
| 2025-11-06 | 5.83x |
| 2025-11-05 | 6.61x |
| 2025-11-04 | 6.78x |
| 2025-11-03 | 9.87x |
| 2025-10-31 | 9.99x |
| 2025-10-30 | 9.61x |
| 2025-10-29 | 9.89x |
| 2025-10-28 | 9.65x |
| 2025-10-27 | 10.18x |
| 2025-10-24 | 9.93x |
| 2025-10-23 | 9.70x |
| 2025-10-22 | 9.51x |
| 2025-10-21 | 9.91x |
| 2025-10-20 | 10.27x |
| 2025-10-17 | 9.77x |
| 2025-10-16 | 10.12x |
| 2025-10-15 | 10.21x |
| 2025-10-14 | 10.00x |
| 2025-10-13 | 10.49x |
| 2025-10-10 | 10.69x |
| 2025-10-09 | 11.00x |
| 2025-10-08 | 11.42x |
| 2025-10-07 | 10.33x |
| 2025-10-06 | 10.34x |
| 2025-10-03 | 10.19x |
| 2025-10-02 | 9.94x |
| 2025-10-01 | 9.80x |
| 2025-09-30 | 9.02x |
| 2025-09-29 | 8.79x |
| 2025-09-26 | 8.78x |
| 2025-09-25 | 8.66x |
| 2025-09-24 | 8.86x |
| 2025-09-23 | 9.38x |
| 2025-09-22 | 9.57x |
| 2025-09-19 | 9.82x |
| 2025-09-18 | 9.70x |
| 2025-09-17 | 9.63x |
| 2025-09-16 | 9.70x |
| 2025-09-15 | 9.49x |
| 2025-09-12 | 9.62x |
| 2025-09-11 | 9.88x |
| 2025-09-10 | 8.75x |
| 2025-09-09 | 9.05x |
| 2025-09-08 | 8.97x |
| 2025-09-05 | 8.90x |
| 2025-09-04 | 8.74x |
| 2025-09-03 | 8.55x |
| 2025-09-02 | 8.77x |
| 2025-08-29 | 8.50x |
| 2025-08-28 | 8.27x |
| 2025-08-27 | 8.22x |
| 2025-08-26 | 8.55x |
| 2025-08-25 | 8.51x |
| 2025-08-22 | 9.00x |
| 2025-08-21 | 8.59x |
| 2025-08-20 | 8.23x |
| 2025-08-19 | 8.21x |
| 2025-08-18 | 8.78x |
| 2025-08-15 | 8.28x |
| 2025-08-14 | 8.05x |
| 2025-08-13 | 7.84x |
| 2025-08-12 | 7.49x |
| 2025-08-11 | 6.90x |
| 2025-08-08 | 6.90x |
| 2025-08-07 | 6.95x |
| 2025-08-06 | 6.59x |
| 2025-08-05 | 6.84x |
| 2025-08-04 | 6.81x |
| 2025-08-01 | 6.52x |
| 2025-07-31 | 6.71x |
| 2025-07-30 | 6.85x |
| 2025-07-29 | 6.90x |
| 2025-07-28 | 7.31x |
| 2025-07-25 | 7.58x |
| 2025-07-24 | 7.46x |
| 2025-07-23 | 7.62x |
| 2025-07-22 | 7.21x |
| 2025-07-21 | 6.87x |
| 2025-07-18 | 7.20x |
| 2025-07-17 | 7.16x |
| 2025-07-16 | 7.08x |
| 2025-07-15 | 6.63x |
| 2025-07-14 | 6.85x |
| 2025-07-11 | 6.74x |
| 2025-07-10 | 7.04x |
| 2025-07-09 | 6.91x |
| 2025-07-08 | 6.92x |
| 2025-07-07 | 6.87x |
| 2025-07-03 | 7.19x |
| 2025-07-02 | 7.00x |
| 2025-07-01 | 7.03x |
| 2025-06-30 | 7.48x |
| 2025-06-27 | 7.81x |
| 2025-06-26 | 8.01x |
| 2025-06-25 | 7.69x |
| 2025-06-24 | 8.00x |
| 2025-06-23 | 7.71x |
| 2025-06-20 | 8.01x |
| 2025-06-18 | 8.09x |
| 2025-06-17 | 8.20x |
| 2025-06-16 | 8.41x |
| 2025-06-13 | 8.33x |
| 2025-06-12 | 8.33x |
| 2025-06-11 | 8.28x |
| 2025-06-10 | 8.12x |
| 2025-06-09 | 7.85x |
| 2025-06-06 | 7.32x |
| 2025-06-05 | 6.94x |
| 2025-06-04 | 7.39x |
| 2025-06-03 | 7.30x |
| 2025-06-02 | 7.47x |
| 2025-05-30 | 6.55x |
Showing the most recent 260 of 499 data points. The chart above shows the full history.
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky